Cargando…

Race to arsenal COVID-19 therapeutics: Current alarming status and future directions

The on-going pandemic of COVID-19 wreaked by a viral infection of SARS-CoV-2, has generated a catastrophic plight across the globe. Interestingly, one of the hallmarks of COVID-19 is the so-called ‘cytokine storm’ due to attack of SARS-Cov-2 in the lungs. Considering, mesenchymal stem cells (MSCs) t...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubey, Ankit Kumar, Singh, Aakansha, Prakash, Shardendu, Kumar, Manoj, Singh, Ashok K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588316/
https://www.ncbi.nlm.nih.gov/pubmed/33121920
http://dx.doi.org/10.1016/j.cbi.2020.109298
_version_ 1783600345442680832
author Dubey, Ankit Kumar
Singh, Aakansha
Prakash, Shardendu
Kumar, Manoj
Singh, Ashok K
author_facet Dubey, Ankit Kumar
Singh, Aakansha
Prakash, Shardendu
Kumar, Manoj
Singh, Ashok K
author_sort Dubey, Ankit Kumar
collection PubMed
description The on-going pandemic of COVID-19 wreaked by a viral infection of SARS-CoV-2, has generated a catastrophic plight across the globe. Interestingly, one of the hallmarks of COVID-19 is the so-called ‘cytokine storm’ due to attack of SARS-Cov-2 in the lungs. Considering, mesenchymal stem cells (MSCs) therapy could contribute against SARS-CoV-2 viruses attack because of their immune modulatory and anti-inflammatory ability linked to their stemness, to the arsenal of treatments for COVID-19. Another novel therapeutic strategies include the blockade of rampant generation of pro-inflammatory mediators like acute respiratory distress syndrome (ARDS), degradation of viral protein capsids by PROTACs, composed of Ubiquitin-proteasome framework, and ubiquitination-independent pathway directing the SARS-CoV-2 nucleocapsid protein (nCoV N) and proteasome activator (PA28γ), etc. This review is consequently an endeavour to highlight the several aspects of COVID-19 with incorporation of important treatment strategies discovered to date and putting the real effort on the future directions to put them into the perspective.
format Online
Article
Text
id pubmed-7588316
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-75883162020-10-27 Race to arsenal COVID-19 therapeutics: Current alarming status and future directions Dubey, Ankit Kumar Singh, Aakansha Prakash, Shardendu Kumar, Manoj Singh, Ashok K Chem Biol Interact Article The on-going pandemic of COVID-19 wreaked by a viral infection of SARS-CoV-2, has generated a catastrophic plight across the globe. Interestingly, one of the hallmarks of COVID-19 is the so-called ‘cytokine storm’ due to attack of SARS-Cov-2 in the lungs. Considering, mesenchymal stem cells (MSCs) therapy could contribute against SARS-CoV-2 viruses attack because of their immune modulatory and anti-inflammatory ability linked to their stemness, to the arsenal of treatments for COVID-19. Another novel therapeutic strategies include the blockade of rampant generation of pro-inflammatory mediators like acute respiratory distress syndrome (ARDS), degradation of viral protein capsids by PROTACs, composed of Ubiquitin-proteasome framework, and ubiquitination-independent pathway directing the SARS-CoV-2 nucleocapsid protein (nCoV N) and proteasome activator (PA28γ), etc. This review is consequently an endeavour to highlight the several aspects of COVID-19 with incorporation of important treatment strategies discovered to date and putting the real effort on the future directions to put them into the perspective. Elsevier B.V. 2020-12-01 2020-10-27 /pmc/articles/PMC7588316/ /pubmed/33121920 http://dx.doi.org/10.1016/j.cbi.2020.109298 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Dubey, Ankit Kumar
Singh, Aakansha
Prakash, Shardendu
Kumar, Manoj
Singh, Ashok K
Race to arsenal COVID-19 therapeutics: Current alarming status and future directions
title Race to arsenal COVID-19 therapeutics: Current alarming status and future directions
title_full Race to arsenal COVID-19 therapeutics: Current alarming status and future directions
title_fullStr Race to arsenal COVID-19 therapeutics: Current alarming status and future directions
title_full_unstemmed Race to arsenal COVID-19 therapeutics: Current alarming status and future directions
title_short Race to arsenal COVID-19 therapeutics: Current alarming status and future directions
title_sort race to arsenal covid-19 therapeutics: current alarming status and future directions
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588316/
https://www.ncbi.nlm.nih.gov/pubmed/33121920
http://dx.doi.org/10.1016/j.cbi.2020.109298
work_keys_str_mv AT dubeyankitkumar racetoarsenalcovid19therapeuticscurrentalarmingstatusandfuturedirections
AT singhaakansha racetoarsenalcovid19therapeuticscurrentalarmingstatusandfuturedirections
AT prakashshardendu racetoarsenalcovid19therapeuticscurrentalarmingstatusandfuturedirections
AT kumarmanoj racetoarsenalcovid19therapeuticscurrentalarmingstatusandfuturedirections
AT singhashokk racetoarsenalcovid19therapeuticscurrentalarmingstatusandfuturedirections